Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is a direct-acting, reversible P2Y12 receptor antagonist used to prevent thrombotic events. It is not a prodrug and does not require hepatic activation.
## Primary Indications
* **Acute Coronary Syndrome (ACS):** In combination with aspirin, for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI).
* **ST-Elevation Myocardial Infarction (STEMI):** In patients treated with fibrinolytic therapy, aspirin, and in patients who have undergone percutaneous coronary intervention (PCI).
## Adult Dosing
* **Loading Dose:** 180 mg orally once.
* **Maintenance Dose:** 90 mg orally twice daily.
* For patients with a history of MI, the maintenance dose may be reduced to 60 mg orally twice daily after 12 months of treatment, provided the patient is at high risk for ischemic events and low risk for bleeding events. This decision should be individualized.
## Pediatric Dosing
Dosing has not been established in pediatric patients.
## Dose Adjustments
* **Hepatic Impairment:** No dose adjustment is needed in patients with mild to moderate hepatic impairment. Use with caution in severe hepatic impairment due to lack of data.
* **Renal Impairment:** No dose adjustment is needed for mild, moderate, or severe renal impairment.
## Contraindications
* Hypersensitivity to ticagrelor or any of its components.
* Active pathological bleeding.
* History of intracerebral hemorrhage.
## Adverse Effects
* **Bleeding:** The most common and serious adverse effect is bleeding (e.g., gastrointestinal, superficial, intracranial). Fatal bleeding has occurred.
* **Dyspnea:** Commonly reported, usually mild and transient.
* **Ventricular pauses:** Transient, asymptomatic, and without clinical sequelae.
* **Bradycardia:** Can be more frequent in patients taking other medications that cause bradycardia.
* **Hyperuricemia and Gout:** Can occur.
* **Nosebleeds, contusion, hematuria.**
## Key Drug Interactions
* **CYP3A4 Substrates:** Ticagrelor is a moderate inhibitor of CYP3A4. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) may increase ticagrelor exposure.
* **CYP3A4 Inducers:** Concomitant use with strong CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine) may decrease ticagrelor exposure and efficacy.
* **Aspirin:** Generally used in combination. High-dose aspirin may reduce ticagrelor's efficacy.
* **Other Antiplatelet Agents/Anticoagulants:** Increased risk of bleeding.
## Monitoring
* **Signs and symptoms of bleeding:** Monitor closely, especially in patients with risk factors.
* **Renal function and uric acid levels:** Periodic monitoring may be considered.
## Clinical Pearls
* Ticagrelor is a reversible P2Y12 inhibitor, which may offer advantages in patients requiring urgent surgery compared to irreversible agents.
* Discontinuation should be avoided unless absolutely necessary, as it significantly increases the risk of stent thrombosis, MI, and death. If discontinuation is necessary, resume as soon as possible.
* Patients taking ticagrelor should be advised to report any signs of bleeding immediately.
---
*This information is intended for healthcare professionals. Always consult the most current prescribing information and institutional protocols for complete details and to ensure patient safety.*
